Sanofi

Sanofi-aventis

Antoine Ravet

Ahmed Abouabdellah

Jacques Froissant

Christian Hoornaert

Frank Marguet

Christophe Pacaud

Jean-Francois Gibert

Antonio Almario Garcia

Frederic Puech

Frédéric Puech

Sylvain Cote Des Combes

Peter Hamley

Jochen Görlitzer

Sylvain Cote-Des-Combes

Regine Bartsch-Li

Jean-François Gibert

Compounds corresponding to the general formula (I) wherein Rrepresents a group C-alkyl, C-cycloalkyl, C-cycloalkyl-C-alkyl, C-alkyl-C-cycloalkyl, C-cycloalkyl-C-cycloalkyl, C-alkylthio-C--alkyl, C-alkoxy-C-alkyl, hydroxy-C-alkyl, hydroxy-C-alkyl-C-cycloalkyl-C-alkyl, hydroxy-C-cycloalkyl, C-fluoroalkyl or C-fluorocycloalkyl; an optionally substituted heterocyclic group; a group C-alkyl substituted with an optionally substituted heterocyclic group; Xrepresents a group chosen from hydrogen, fluorine, chlorine and bromine atoms or a group C-alkyl, C-cycloalkyl, C-cycloalkyl-C-alkyl, C-fluoroalkyl or cyano; and Rrepresents an aryl group such as phenyl or naphthyl, optionally substituted with one or more substituents,in the form of the base or of an acid-addition salt, and the therapeutic use thereof.

3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta

The invention relates to compounds corresponding to the general formula (I):  The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.

Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application

The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, &#x2014;COORc-CO&#x2014;Rc or &#x2014;CO&#x2014;NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors.

Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof

Compounds corresponding to the general formula (I) 

[object Object]

The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ishaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula alkylene group; a salt thereof, or a hydrate or a solvate of said compound or said salt; where the variables are as defined in the attached specification.

Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors

The present invention provides a compound of the formula (I): in which R, R, R, A and n are described and set forth more fully herein. Also provided are their preparation and their application in therapy.

Arylalkylcarbamate derivatives and production thereof

Growing community of inventors

Paris, France

Antoine Ravet